Targeting Proteostasis as a breakthrough in Alzheimer’s disease therapy
The Growing Challenge of Alzheimer’s Disease
6.7 million Americans are living with Alzheimer’s disease, 55 million people worldwise
What happens in brain during Alzheimer’s disease?
LOSS of PROTEOSTASIS. Patients with Alzheimer’s disease experience a loss of the balance between protein synthesis, folding, modifications and degradation.
Activating proteasome as a therapeutic target
We have developed a set of activators which enhance function of the proteasome, a key factor in the degradation of proteins. Our compounds are stable and make it to brain
Effective treatment strategy
In the lab we can reverse Alzheimer’s disease learning and memory deficits with our compounds